Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.
Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands.
They have:
- Stylish products
- World Class Management Team
- A proven and repeatable strategy for success
Experienced and proven luxury cannabis concentrates brand
One of the tops selling vape brands in WA State with a loyal customer base
Largest standalone oil manufacturer in the state of WA
Consistent sales growth over 3 years with a verified marketing blueprint
Offers investors exposure to a premium luxury cannabis brand
Demonstrated to have a winning formula to become the top vape company in WA
Massive growth opportunity available with expansion into OR, NV and CA
Mydecine announces an LOI to co-develop its own digital therapeutics platform, in partnership with Maya Health.
Cybin Inc provides a year-end update highlighting drug and IP development as well as international expansion.
Optimi Health receives its Health Canada Dealers' License and initiates new Quality Assurance Department.
2021 was two different "years" for the psychedelic drug industry. Impressive progress in drug R&D and clinics; stocks pushed down to absurdly lean multiples.
Awakn Life Sciences reports its Q3 for fiscal 2021. Highlights include key IP and clinic acquisitions, and the company's first revenues.
MindMed's Phase IIa clinical trial of LSD for adults ADHD is officially underway, enrolling patients.